Seroprevalence surveys suggest that more than a third and possibly more than half of the
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …

Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been
reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid …

Abstract Background The B. 1.1. 529 (omicron) variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng …

Background The duration and effectiveness of immunity from infection with and vaccination
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are relevant to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity
varies between individuals, and immune responses correlate with vaccine efficacy. Using …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated …

Background The continued success of the COVID-19 vaccination programme in the UK will
depend on widespread uptake of booster vaccines. However, there is evidence of hesitancy …

Background A correlate of protection (CoP) is an immunological marker associated with
protection against infection. Despite an urgent need, a CoP for SARS-CoV-2 is currently …

Heterologous Boost with Beta Variant Spike Vaccine In a small trial of boost immunization
with the mRNA vaccine originally received or with heterologous boosting with spike proteins …

Three COVID-19 vaccines have received FDA-authorization and are in use in the United
States, but there is limited head-to-head data on the durability of the immune response …